Navigation Links
Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer
Date:8/22/2014

LA JOLLA, Cali., Aug. 22, 2014 /PRNewswire/ -- Research presented at the 29th Annual International Papillomavirus Conference shows that a therapy being developed by Hera Therapeutics Inc. combats three types of human papillomavirus, including the two that cause 70 percent of all cervical cancer.

When tested in several cultured human cell models, HTI-1968 blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according to Louise T. Chow, Ph.D. and Thomas Broker, Ph.D., who presented the findings at the Seattle conference. The National Institute of Allergy and Infectious Diseases in the National Institutes of Health funded Chow's work at the University of Alabama, Birmingham.

"HTI-1968 is potent and selective, inhibiting the growth of these high-risk HPV types. Dr. Chow's findings, though early stage, offer hope to millions of women infected by one of these high-risk HPV types, including two that are responsible for 70 percent of cervical cancer cases," said Hera Therapeutics CEO Karl Hostetler, M.D.. Currently surgery is the only therapy available to women who have persistent infection with these types of HPV and show signs of abnormal cells.

Hera Therapeutics is developing a topical, non-surgical approach to treat HPV, which could alter the standard of care while preserving structural integrity of the cervix.

Approximately 96 million people worldwide, men and women, are infected with HPV-16 or HPV-18, according to the Centers for Disease Control. Almost 4,000 women in the U.S. die from invasive cervical cancer each year, according to the CDC.

While cervical cancer vaccines prevent infection from the disease, they are not approved by the FDA for marketing to people over 26-years-old and have not demonstrated efficacy in people already infected with the HPV virus.

About Hera Therapeutics Inc.

Using a new medicinal chemistry platform, Hera Therapeutics Inc. is focused on the research, development and commercialization of direct acting antivirals for infections with the human papillomavirus, herpes group viruses, HIV and animal retroviruses.

Hera Therapeutics was founded in 2012 by Karl Hostetler, M.D., a professor emeritus at University of California, San Diego, who was previously a founder of three biotech companies, including Chimerix, Triangle Pharmaceuticals and Vical.


'/>"/>
SOURCE Hera Therapeutics Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients
2. Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite
3. Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting
4. Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
5. FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol
6. TRU-D Tested in Most Comprehensive UV Disinfection Study to Date
7. Major Clinical Study Supports NIPT As First Line Screening Test For All Pregnant Women
8. R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study
9. Study: 1 out of 5 adult orthopaedic trauma patients sought additional providers for narcotic prescriptions
10. Study Helps Medical Education Leaders Navigate the New Regulatory and Financial Landscape
11. BioSpecifics Technologies Corp. Announces Initiation of Phase 2 Clinical Study of CCH for Treatment of Lipoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 2, 2016 ... "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, ... Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - ... market is valued at USD 60.22 Billion in ... a CAGR of 5.5% during the forecast period ...
(Date:12/2/2016)... 2, 2016 On Thursday, December ... excellence in research, development and innovation in the biopharmaceutical ... was held in the presence of Sergey Tsyb, Vice ... Russian Federation , Natalia Sanina, First Vice Chairman ... , Head of Roszdravnadzor, National Service of Control in ...
(Date:12/2/2016)... -- bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, ... von Kenia eingeführt. Continue Reading ... ... (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical wurde durch die Clinton ...
Breaking Medicine Technology:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... edition of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic ... health while maintaining fulfilling lives. “We are prolonging life 6 years in the ...
(Date:12/2/2016)... ... 2016 , ... Sourced from the Isbre Springs beneath the 5,000 year old ... purity of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent ... in several ShopRite and FoodTown stores in NJ and received rave comments from consumers. ...
(Date:12/2/2016)... San Francisco, CA (PRWEB) , ... December 02, ... ... in digitally-enabled care journeys, announced today that it has raised $6.0 million in ... are inspired by Clarify Health’s conviction that patients and their caregivers can receive ...
(Date:12/2/2016)... ... 2016 , ... ‘Tis the season for giving! Today, 20 creative teams across ... Partnership and the Drug Enforcement Administration as part of the National Red Ribbon Week ... schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. Be ...
(Date:11/30/2016)... ... 30, 2016 , ... Standard Process, Inc. is proud to ... recognition of the largest closely held companies headquartered in Wisconsin. This marks the ... Standard Process was awarded the Talent Award for providing outstanding employee benefits. ...
Breaking Medicine News(10 mins):